Pharmacovigilance and Drug Safety Software Market Outlook: Regulatory Compliance and Patient Safety Enhancement Opportunities

According to IMARC Group's latest research publication, The global pharmacovigilance and drug safety software market size reached USD 226.2 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 361.7 Million by 2034, exhibiting a growth rate (CAGR) of 5.19% during 2026-2034.

How AI is Reshaping the Future of Pharmacovigilance and Drug Safety Software Market

• Automated Adverse Event Reporting and Data Extraction: Natural language processing algorithms extract structured information from unstructured medical narratives, automatically populating safety databases with minimal human intervention. AI-powered systems process approximately 50 million report pairs per second, identifying duplicate cases and reducing data entry time by up to 40% across pharmaceutical organizations.
• Intelligent Signal Detection and Pattern Recognition: Machine learning models analyze massive datasets from electronic health records, spontaneous reporting systems, and social media to identify potential safety signals earlier than traditional methods. Advanced algorithms detect subtle adverse drug reaction patterns by correlating clinical data, drug classifications, and protein interaction networks with exceptional accuracy.
• Predictive Risk Assessment and Causality Analysis: AI systems evaluate historical case data to predict adverse drug reactions before they occur, enabling proactive safety interventions. Deep learning models identify patient populations at heightened risk for specific adverse events, facilitating specialized monitoring and targeted risk management strategies across clinical trial phases.

Explore Updated 2026 Market Trends & Analysis

Pharmacovigilance and Drug Safety Software Industry Overview:

Regulatory frameworks worldwide are undergoing significant transformation to address AI integration in drug safety monitoring. The FDA released its first draft guidance on artificial intelligence in drug development in January 2025, establishing a risk-based credibility model for AI system validation in pharmacovigilance. The FDA's Emerging Drug Safety Technology Program, launched earlier, continues supporting AI adoption through collaborative industry meetings and non-binding discussions. In December 2025, the FDA finalized comprehensive safety reporting guidances for sponsors and investigators, modernizing adverse event reporting requirements for investigational drugs, biologics, and medical devices across clinical studies.

Pharmacovigilance and Drug Safety Software Market Trends & Drivers

The explosive growth of adverse drug reactions worldwide is fundamentally reshaping pharmacovigilance priorities across pharmaceutical organizations. Adverse drug reactions account for approximately 5% of urgent hospitalizations globally, creating substantial economic burdens for healthcare systems already strained by increasing patient volumes. Traditional pharmacovigilance systems struggle with underreporting issues—median reporting rates reach only 6% of actual adverse events—threatening patient safety by hindering early safety signal detection. This gap drives pharmaceutical companies, contract research organizations, and regulatory agencies toward automated software solutions capable of capturing adverse events from diverse sources including electronic health records, patient support programs, and direct consumer reports. The complexity of modern drug therapies, particularly biologics and combination treatments, generates unprecedented volumes of safety data requiring sophisticated management platforms that ensure regulatory compliance while maintaining data integrity across global operations.

Technology advancement is fundamentally transforming how pharmaceutical companies approach drug safety monitoring and regulatory compliance. Major platform providers launched AI-native capabilities throughout the industry. In late 2025, ArisGlobal announced NavaX processing 700,000 cases annually with plans scaling to 2.5 million cases by mid-2026, while introducing agentic AI capabilities across safety workflows. Oracle achieved recognition as a Leader in the IDC MarketScape for Worldwide Life Science Pharmacovigilance Technology Solutions in September 2025, with analysts highlighting its connected ecosystem for precision pharmacovigilance. Veeva Systems scheduled AI Agents release for April 2026, introducing autonomous capabilities for safety case processing and operational tasks. In March 2025, Tech Mahindra partnered with NVIDIA launching an AI-powered pharmacovigilance solution delivering 40% faster turnaround times for adverse drug reaction cases, 30% improvement in data accuracy, and 25% reduction in operational costs. These technological leaps enable pharmaceutical organizations to handle exponentially growing data volumes while maintaining compliance with evolving global regulatory standards including FDA 21 CFR Part 11 and EU GMP Annex 11 requirements.

Outsourcing trends and strategic partnerships are reshaping the pharmacovigilance landscape as pharmaceutical companies seek operational flexibility and cost optimization. The industry is moving away from fully integrated pharmaceutical operations toward collaborative models with specialized service providers covering medical writing, clinical trial data management, and comprehensive safety monitoring. Contract research organizations increasingly adopt advanced pharmacovigilance platforms to manage multiple client safety databases simultaneously, with systems offering multivigilance capabilities enabling data segregation while maintaining centralized oversight. Qinecsa Solutions acquired Insife ApS in March 2024, enhancing its technology portfolio with innovative pharmacovigilance platforms. EPS Corporation, Japan's largest CRO, selected ArisGlobal's LifeSphere MultiVigilance in late 2025, specifically citing scalability and performance for multilingual sponsor bases while aligning with PMDA regulatory requirements. Cloud-based software delivery models dominate new deployments, providing pharmaceutical organizations with continuous validation, quarterly feature releases, and elimination of local IT infrastructure overhead while ensuring compliance with stringent data security and privacy regulations governing patient health information across multiple jurisdictions.

Leading Companies Operating in the Global Pharmacovigilance and Drug Safety Software Industry:

• AB Cube S.A.S.
• Anju Software
• ArisGlobal
• Ennov
• Extedo
• Honeywell International Inc.
• IQVIA Inc.
• Oracle
• Sarjen Systems Pvt. Ltd.
• United BioSource LLC
• Veeva Systems Inc.

Pharmacovigilance and Drug Safety Software Market Report Segmentation:

By Functionality:

• Adverse Event Reporting Software
• Drug Safety Audits Software
• Issue Tracking Software
• Fully Integrated Software

Adverse event reporting software dominates the market as it serves as the critical foundation for regulatory compliance, enabling systematic capture, storage, and management of large adverse event data volumes while streamlining reporting processes to meet FDA, EMA, and WHO global standards.

By Delivery Mode:

• On-premises
• Cloud-based

On-premises delivery holds the largest share in the market as it provides organizations enhanced control over sensitive patient data, greater customization flexibility for complex IT environments, maintained data sovereignty for regulatory compliance, and elimination of network latency concerns for mission-critical pharmacovigilance operations.

By End Use:

• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations
• Business Process Outsourcing Firms
• Others

Contract research organizations have the largest market share owing to their specialized expertise in providing comprehensive outsourced pharmacovigilance services, ability to scale resources according to project requirements, and proficiency in navigating complex global regulatory landscapes while supporting multiple pharmaceutical clients simultaneously.

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America exhibits a clear dominance in the pharmacovigilance and drug safety software market due to its robust pharmaceutical industry infrastructure, stringent FDA regulatory requirements, advanced healthcare IT ecosystem, and concentrated presence of leading technology vendors and life sciences organizations.

Recent News and Developments in Pharmacovigilance and Drug Safety Software Market

• December 2025: The U.S. FDA released two final guidance documents on safety reporting in clinical research—"Investigator Responsibilities: Safety Reporting for Investigational Drugs and Devices" and "Sponsor Responsibilities: Safety Reporting Requirements and Safety Assessment for IND and Bioavailability/Bioequivalence Studies"—modernizing adverse event reporting expectations and replacing prior guidelines to improve overall safety reporting quality across the pharmaceutical industry.
• November 2025: Veeva Systems announced the scheduled April 2026 release of AI Agents across all Vault applications, including Safety & Quality AI agents designed to introduce agentic AI capabilities for automated safety case processing, intelligent triage operations, and autonomous workflow management, representing a significant advancement in pharmacovigilance automation.
• March 2025: Tech Mahindra partnered with NVIDIA to launch an AI-powered pharmacovigilance solution transforming drug safety monitoring and pharmaceutical data management. The innovative platform delivers 40% faster turnaround times for adverse drug reaction case handling, 30% improvement in data accuracy, and 25% reduction in operational costs for pharmaceutical organizations.
• February 2023: ArisGlobal launched its regulatory information management solution purpose-built for investigational-stage companies. The new product targets emerging life sciences and medical device companies, focusing on essential functionality needed to achieve clinical and regulatory milestones while maintaining compliance throughout the development lifecycle.
• March 2024: Qinecsa Solutions acquired Insife ApS, a Danish firm recognized for innovative pharmacovigilance platforms, strategically enhancing Qinecsa's technology capabilities and service offerings in drug safety. The acquisition strengthens the company's position in the European pharmacovigilance market and expands its AI-driven safety monitoring solutions.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.